Pharmacokinetics oral intravenous omeprazole patients Zollinger-Ellison syndrome pharmacokinetics pharmacodynamics oral IV single dose patients Zollinger-Ellison syndrome dose gastric acid hypersecretion basis altered pharmacokinetics patient single IV bolus omeprazole mg single oral dose omeprazole mg Intravenous oral omeprazole doses week Gastric acid secretion plasma concentrations omeprazole drug administration patient area plasma concentration curve clearance volume distribution IV omeprazole administration area plasma concentration curve peak plasma concentration time peak oral omeprazole administration different normal subjects patients peptic ulcer disease Mean SEM bioavailability oral omeprazole patients similar bioavailability normal subjects patients bioavailability normal subjects patients bioavailability others basal outputs patients patients inverse correlation bioavailability basal acid output mean SEM elimination half-lives IV oral omeprazole different hours normal subjects duration action elimination half-life drug area plasma concentration curve mean durations action IV oral omeprazole different hours altered pharmacokinetics drug requirement omeprazole patients Zollinger-Ellison syndrome contrast previous study oral IV omeprazole duration action intermittent bolus administration parenteral omeprazole need continuous infusion histamine antagonists patients parenteral antisecretory drugs Furthermore IV dose hours acid secretion patients dose interval patients parenteral drug therapy 